EMN Guideline Team

Various reviews, guidelines and recommendation papers are produced under the EMN umbrella. To collect & better coordinate the various proposals and manuscripts, a guideline team is in place: Monika Engelhardt from Germany, Niels van de Donk from the Netherlands, Francesca Gay from Italy and Evangelos Terpos from Greece.

When submitting a proposal, authors are kindly invited to double check if the same topic was already recently covered by the EMN or other research group.

Here you will find the latest information and what topics have been prioritized by the EMN in the last Trialist Forum, for further reference:

Baveno 2023 – EMN Guideline Team

Review/consensus/guideline articles

  • Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN) view
  • Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network view
  • Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project view
  • COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network view
  • 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: How to distinguish (and manage) Dr. Jekyll and Mr. Hyde view
  • Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) view
  • Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network view
  • Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network. view
  • Management of Patients With Multiple Myeloma in the Era of COVID-19 Pandemic: A Consensus Paper From the European Myeloma Network (EMN) view
  • Time From First Symptom Onset to the Final Diagnosis of Multiple Myeloma (MM) – Possible Risks and Future Solutions: Retrospective and Prospective ‘Deutsche Studiengruppe MM’ (DSMM) and ‘European Myeloma Network’ (EMN) Analysis view
  • Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma: A Consensus Statement From The European Myeloma Network view
  • Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. view
  • Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. view
  • Insights on Multiple Myeloma Treatment Strategies view
  • European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when view
  • Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) view
  • European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias view
  • From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives view
  • Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network view
  • Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network view
  • Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) view
  • Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) view
  • Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders view
  • Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN) view
  • European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma view
  • The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network view
  • Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network view
  • European Myeloma Network guidelines for the management of multiple myeloma-related complications view
  • European myeloma network: the value of collaborative research view
  • Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders view
  • The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network view
  • A new co-operative group: the European Myeloma Network Trialist Group view
  • European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. view
  • Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement view
  • Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. view
  • Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. view
  • Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). view